Thalidomide for the treatment of refractory multiple myeloma: Association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome

Tsunayaki Kakimoto, Yutaka Hattori, Shinichiro Okamoto, Norihide Sato, Tamihiro Kamata, Masaya Yamaguchi, Kunihiko Morita, Taketo Yamada, Nobuyuki Takayama, Hideo Uchida, Naoki Shimada, Yusuke Tanigawara, Yasuo Ikeda

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Recent reports showed that thalidomide has anti-angiogenic activity and is effective for the treatment of refractory multiple myeloma (MM). We examined the relationship between the clinical efficacy and adverse effects of thalidomide and the plasma concentrations of this drug as well as angiogenic growth factors in refractory MM. Ten out of twenty-four evaluable patients (42%) showed more than 25% reduction of M-protein, and eight (33%) achieved more than 50% reduction. These changes were associated with restoration of anemia and recovery of normal immunoglobulin level. Somnolence and headache, constipation, peripheral neuropathy and skin rash were frequently observed, but were well tolerated. However, grade 2-4 severe neutropenia was also observed in nine cases. These adverse effects other than neutropenia occurred more frequently in the patients with higher plasma concentrations of thalidomide (≥2.0 μg/ml at 12 h after the last administration) and were readily alleviated by dose reduction. In contrast, neutropenia developed regardless of the plasma concentration. Plasma concentrations of angiogenic growth factors were frequently elevated before treatment. After thalidomide treatment, these growth factor levels tend to decrease to near-normal ranges in responders but were still high in most non-responders. After thalidomide treatment, plasma vascular endothelial growth factor (VEGF) level was significantly reduced in responders (P=0.025), but not in non-responders (P=0.37). Reduction of plasma VEGF level might be an important indicator for anti-myeloma effect of thalidomide.

Original languageEnglish
Pages (from-to)1029-1036
Number of pages8
JournalJapanese Journal of Cancer Research
Volume93
Issue number9
Publication statusPublished - 2002 Sep 1

Fingerprint

Thalidomide
Angiogenesis Inducing Agents
Multiple Myeloma
Intercellular Signaling Peptides and Proteins
Neutropenia
Vascular Endothelial Growth Factor A
Therapeutics
Peripheral Nervous System Diseases
Constipation
Exanthema
Headache
Immunoglobulins
Anemia
Reference Values
Pharmaceutical Preparations
Proteins

Keywords

  • Fibroblast growth factor
  • Multiple myeloma
  • Neutropenia
  • Thalidomide
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Thalidomide for the treatment of refractory multiple myeloma : Association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome. / Kakimoto, Tsunayaki; Hattori, Yutaka; Okamoto, Shinichiro; Sato, Norihide; Kamata, Tamihiro; Yamaguchi, Masaya; Morita, Kunihiko; Yamada, Taketo; Takayama, Nobuyuki; Uchida, Hideo; Shimada, Naoki; Tanigawara, Yusuke; Ikeda, Yasuo.

In: Japanese Journal of Cancer Research, Vol. 93, No. 9, 01.09.2002, p. 1029-1036.

Research output: Contribution to journalArticle

Kakimoto, Tsunayaki ; Hattori, Yutaka ; Okamoto, Shinichiro ; Sato, Norihide ; Kamata, Tamihiro ; Yamaguchi, Masaya ; Morita, Kunihiko ; Yamada, Taketo ; Takayama, Nobuyuki ; Uchida, Hideo ; Shimada, Naoki ; Tanigawara, Yusuke ; Ikeda, Yasuo. / Thalidomide for the treatment of refractory multiple myeloma : Association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome. In: Japanese Journal of Cancer Research. 2002 ; Vol. 93, No. 9. pp. 1029-1036.
@article{6eed4a1f540e406aa686ae9784e0d7fa,
title = "Thalidomide for the treatment of refractory multiple myeloma: Association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome",
abstract = "Recent reports showed that thalidomide has anti-angiogenic activity and is effective for the treatment of refractory multiple myeloma (MM). We examined the relationship between the clinical efficacy and adverse effects of thalidomide and the plasma concentrations of this drug as well as angiogenic growth factors in refractory MM. Ten out of twenty-four evaluable patients (42{\%}) showed more than 25{\%} reduction of M-protein, and eight (33{\%}) achieved more than 50{\%} reduction. These changes were associated with restoration of anemia and recovery of normal immunoglobulin level. Somnolence and headache, constipation, peripheral neuropathy and skin rash were frequently observed, but were well tolerated. However, grade 2-4 severe neutropenia was also observed in nine cases. These adverse effects other than neutropenia occurred more frequently in the patients with higher plasma concentrations of thalidomide (≥2.0 μg/ml at 12 h after the last administration) and were readily alleviated by dose reduction. In contrast, neutropenia developed regardless of the plasma concentration. Plasma concentrations of angiogenic growth factors were frequently elevated before treatment. After thalidomide treatment, these growth factor levels tend to decrease to near-normal ranges in responders but were still high in most non-responders. After thalidomide treatment, plasma vascular endothelial growth factor (VEGF) level was significantly reduced in responders (P=0.025), but not in non-responders (P=0.37). Reduction of plasma VEGF level might be an important indicator for anti-myeloma effect of thalidomide.",
keywords = "Fibroblast growth factor, Multiple myeloma, Neutropenia, Thalidomide, Vascular endothelial growth factor",
author = "Tsunayaki Kakimoto and Yutaka Hattori and Shinichiro Okamoto and Norihide Sato and Tamihiro Kamata and Masaya Yamaguchi and Kunihiko Morita and Taketo Yamada and Nobuyuki Takayama and Hideo Uchida and Naoki Shimada and Yusuke Tanigawara and Yasuo Ikeda",
year = "2002",
month = "9",
day = "1",
language = "English",
volume = "93",
pages = "1029--1036",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Thalidomide for the treatment of refractory multiple myeloma

T2 - Association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome

AU - Kakimoto, Tsunayaki

AU - Hattori, Yutaka

AU - Okamoto, Shinichiro

AU - Sato, Norihide

AU - Kamata, Tamihiro

AU - Yamaguchi, Masaya

AU - Morita, Kunihiko

AU - Yamada, Taketo

AU - Takayama, Nobuyuki

AU - Uchida, Hideo

AU - Shimada, Naoki

AU - Tanigawara, Yusuke

AU - Ikeda, Yasuo

PY - 2002/9/1

Y1 - 2002/9/1

N2 - Recent reports showed that thalidomide has anti-angiogenic activity and is effective for the treatment of refractory multiple myeloma (MM). We examined the relationship between the clinical efficacy and adverse effects of thalidomide and the plasma concentrations of this drug as well as angiogenic growth factors in refractory MM. Ten out of twenty-four evaluable patients (42%) showed more than 25% reduction of M-protein, and eight (33%) achieved more than 50% reduction. These changes were associated with restoration of anemia and recovery of normal immunoglobulin level. Somnolence and headache, constipation, peripheral neuropathy and skin rash were frequently observed, but were well tolerated. However, grade 2-4 severe neutropenia was also observed in nine cases. These adverse effects other than neutropenia occurred more frequently in the patients with higher plasma concentrations of thalidomide (≥2.0 μg/ml at 12 h after the last administration) and were readily alleviated by dose reduction. In contrast, neutropenia developed regardless of the plasma concentration. Plasma concentrations of angiogenic growth factors were frequently elevated before treatment. After thalidomide treatment, these growth factor levels tend to decrease to near-normal ranges in responders but were still high in most non-responders. After thalidomide treatment, plasma vascular endothelial growth factor (VEGF) level was significantly reduced in responders (P=0.025), but not in non-responders (P=0.37). Reduction of plasma VEGF level might be an important indicator for anti-myeloma effect of thalidomide.

AB - Recent reports showed that thalidomide has anti-angiogenic activity and is effective for the treatment of refractory multiple myeloma (MM). We examined the relationship between the clinical efficacy and adverse effects of thalidomide and the plasma concentrations of this drug as well as angiogenic growth factors in refractory MM. Ten out of twenty-four evaluable patients (42%) showed more than 25% reduction of M-protein, and eight (33%) achieved more than 50% reduction. These changes were associated with restoration of anemia and recovery of normal immunoglobulin level. Somnolence and headache, constipation, peripheral neuropathy and skin rash were frequently observed, but were well tolerated. However, grade 2-4 severe neutropenia was also observed in nine cases. These adverse effects other than neutropenia occurred more frequently in the patients with higher plasma concentrations of thalidomide (≥2.0 μg/ml at 12 h after the last administration) and were readily alleviated by dose reduction. In contrast, neutropenia developed regardless of the plasma concentration. Plasma concentrations of angiogenic growth factors were frequently elevated before treatment. After thalidomide treatment, these growth factor levels tend to decrease to near-normal ranges in responders but were still high in most non-responders. After thalidomide treatment, plasma vascular endothelial growth factor (VEGF) level was significantly reduced in responders (P=0.025), but not in non-responders (P=0.37). Reduction of plasma VEGF level might be an important indicator for anti-myeloma effect of thalidomide.

KW - Fibroblast growth factor

KW - Multiple myeloma

KW - Neutropenia

KW - Thalidomide

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=0036748453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036748453&partnerID=8YFLogxK

M3 - Article

C2 - 12359057

AN - SCOPUS:0036748453

VL - 93

SP - 1029

EP - 1036

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 9

ER -